千金药业
(600479)
| 流通市值：47.79亿 | | | 总市值：48.42亿 |
| 流通股本：4.19亿 | | | 总股本：4.24亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,714,645,993.63 | 1,924,281,007.44 | 1,000,740,881.98 | 3,798,485,330.31 |
| 营业收入 | 2,714,645,993.63 | 1,924,281,007.44 | 1,000,740,881.98 | 3,798,485,330.31 |
| 二、营业总成本 | 2,475,132,343.8 | 1,744,641,940.28 | 921,113,129.34 | 3,356,217,415.98 |
| 营业成本 | 1,464,599,086.37 | 1,055,148,991.3 | 543,000,178.06 | 2,046,728,898.67 |
| 税金及附加 | 28,518,550.15 | 19,315,782.14 | 10,300,418.73 | 38,002,022.56 |
| 销售费用 | 656,039,950.54 | 438,686,688.89 | 248,837,009.34 | 904,270,042.72 |
| 管理费用 | 195,171,032.54 | 123,360,245.32 | 59,821,866.11 | 263,579,443.06 |
| 研发费用 | 144,395,569.53 | 114,750,778.24 | 60,460,413.73 | 149,067,057.97 |
| 财务费用 | -13,591,845.33 | -6,620,545.61 | -1,306,756.63 | -45,430,049 |
| 其中:利息费用 | 1,645,932.42 | 1,389,377.97 | 911,037.42 | 1,668,222.98 |
| 其中:利息收入 | 18,890,712.67 | 10,290,307 | 4,811,591.39 | 51,394,739.11 |
| 加:公允价值变动收益 | -1,009,742.23 | 2,883,219.09 | 990,327.47 | -1,597,097.03 |
| 加:投资收益 | 2,419,826.5 | -2,924,835.31 | -2,724,805.78 | 17,469,067.27 |
| 资产减值损失(新) | -1,996,475.41 | 833,771.59 | - | -2,571,229.74 |
| 信用减值损失(新) | -10,262,645.86 | -15,281,274.91 | -10,024,548.49 | -18,269,569.55 |
| 其他收益 | 11,925,242.84 | 8,739,683.79 | 3,416,277.39 | 24,640,571.39 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 240,589,855.67 | 173,889,631.41 | 71,285,003.23 | 461,939,656.67 |
| 加:营业外收入 | 2,132,361.67 | 804,821.54 | 642,228.73 | 996,260.63 |
| 减:营业外支出 | 1,153,783.95 | 949,164.02 | 402,261.05 | 2,516,446.01 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 241,568,433.39 | 173,745,288.93 | 71,524,970.91 | 460,419,471.29 |
| 减:所得税费用 | 28,203,388.52 | 24,677,298.61 | 10,517,120.93 | 65,402,588.87 |
| 六、净利润 | 213,365,044.87 | 149,067,990.32 | 61,007,849.98 | 395,016,882.42 |
| 持续经营净利润 | 213,365,044.87 | 149,067,990.32 | 61,007,849.98 | 395,016,882.42 |
| 归属于母公司股东的净利润 | 168,076,563.28 | 117,723,047.32 | 46,198,047.86 | 320,405,834.89 |
| 少数股东损益 | 45,288,481.59 | 31,344,943 | 14,809,802.12 | 74,611,047.53 |
| (一)基本每股收益 | 0.4 | 0.28 | 0.11 | 0.76 |
| (二)稀释每股收益 | 0.4 | 0.28 | 0.11 | 0.76 |
| 八、其他综合收益 | -75,373.07 | -246.99 | -246.99 | 185,415.06 |
| 归属于母公司股东的其他综合收益 | -75,373.07 | -246.99 | -246.99 | 185,415.06 |
| 九、综合收益总额 | 213,289,671.8 | 149,067,743.33 | 61,007,602.99 | 395,202,297.48 |
| 归属于母公司股东的综合收益总额 | 168,001,190.21 | 117,722,800.33 | 46,197,800.87 | 320,591,249.95 |
| 归属于少数股东的综合收益总额 | 45,288,481.59 | 31,344,943 | 14,809,802.12 | 74,611,047.53 |
| 公告日期 | 2024-10-30 | 2024-08-28 | 2024-04-30 | 2024-04-12 |
| 审计意见(境内) | | | | 标准无保留意见 |